期刊文献+

沙格列汀改善2型糖尿病患者β细胞功能的Meta分析 被引量:36

Effect of Saxagliptin on the β-cell Function of Patients with Type 2 Diabetes: A Systematic Review
原文传递
导出
摘要 目的系统评价沙格列汀改善2型糖尿病患者β细胞功能的效果。方法计算机检索Cochrane图书馆、PubMed、EMbase、CNKI、VIP和CBM,查找沙格列汀改善2型糖尿病患者β细胞功能的随机对照试验(RCT),检索时限均为从建库至2011年11月,文种限中、英文。按纳入与排除标准筛选文献、提取资料和评价纳入研究的方法学质量后,采用RevMan 5.0软件进行Meta分析。结果共纳入5个RCT,2 815例患者。Meta分析结果显示:在改善2型糖尿病患者Homa-β方面,沙格列汀(或沙格列汀+常规治疗)2.5 mg、5 mg、10 mg组均优于对照组[MD=8.03,95%CI(4.57,11.48),P<0.000 01;MD=7.50,95%CI(4.27,10.73),P<0.000 01;MD=17.45,95%CI(13.93,20.97),P<0.000 01];而在改善Homa-IR方面,沙格列汀5 mg组优于对照组[MD=–0.16,95%CI(–0.27,–0.05),P=0.005],而沙格列汀2.5 mg、10 mg组与对照组相当[MD=–0.05,95%CI(–0.18,0.08),P=0.47;MD=–0.18,95%CI(–0.60,0.24),P=0.4]。结论现有证据表明,沙格列汀在改善β细胞功能及胰岛素耐受方面有一定疗效。由于纳入研究随访时间较短、样本量较小,上述结论尚需高质量、大样本、长期随访的RCT进一步验证。 Objective To evaluate the effects of saxagliptin on β cell function of type 2 diabetic patients. Meth- ods The Cochrane Library, PubMed, EMbase, CBM, VIP, and CNKI were searched from their establishment to No- vember, 2011, for relevant randomized controlled trials on the effects of saxagliptin on 13 cell function in type 2 diabetic patients. Language was limited to Chinese and English only. Two reviewers independently screened the literature ac- cording to the inclusion and exclusion criteria, extracted the data, and evaluated and cross-checked the methodological quality. Then meta-analysis was conducted using RevMan 5.0 software. Results Five RCTs were included. The results of meta-analysis showed that: HOMA-B was significantly increased in the saxagliptin (or saxagliptin plus routine treatment) 2.5 mg, 5 mg, and 10 mg groups (MD=8.03, 95%CI 4.57 to 11.48, P〈0.000 01; MD=7.50, 95%CI 4.27 to 10.73, P〈0.000 01; MD=17.45, 95%CI 13.93 to 20.97, P〈0.000 01); HOMA-IR was similar between saxagliptin 2.5 or 10 mg group, and control group (MD= -0.05, 95%CI -0.18 to 0.08, P=0.47; MD= -0.18, 95%CI -0.60 to 0.24, P=0.4). Conclusion Current evidence shows that saxagliptin is effective in improving 13 cell function and insulin resistance. Due to short follow-up and small sample size, this conclusion has to be further proved by more high-quality RCTs.
出处 《中国循证医学杂志》 CSCD 2013年第4期436-440,共5页 Chinese Journal of Evidence-based Medicine
关键词 沙格列汀 2型糖尿病 胰岛Β细胞功能 胰岛素抵抗 META分析 系统评价 随机对照试验 Saxagliptin Type 2 diabetes mellitus islet ~ cell function Insulin resistance Meta-analysis Systematicreview Randomized controlled trial
  • 相关文献

参考文献12

  • 1叶林秀,郭昆全,杨茂平,邱红.老年2型糖尿病患者氧化应激状态与β细胞功能的研究[J].中国老年学杂志,2009,29(24):3292-3293. 被引量:3
  • 2Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibi- tors for the treatment of type 2 diabetes mellitus. Pharmacotherapy, 2010, 30(5): 463-484.
  • 3Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from: www.cochrane-handbook, org.
  • 4Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes, Obesity And Metabolism, 2008, 10(5): 376-386.
  • 5Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes:A Randomised Controlled Trial. Int J Clin Pract, 2009, 63(9): 1395-1406.
  • 6DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxzgliptin when added to metformin therapy in patients with inad- equately controlled type 2 diabetes with metformin alone. Diabetes Care, 2009, 32(9): 1649-1655.
  • 7Hollander P, Li J, Allen E, et al. Saxagliptin added to a thiazolidin- edione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab, 2009, 94(12): 4810-4819.
  • 8Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin, 2009, 25(10): 2401-2411.
  • 9叶兴蓉,王炜,孙海清,陈建明,沈国玉,肖欣荣.老年2型糖尿病患者体重指数与胰岛β细胞功能及胰岛素抵抗相关性的探讨[J].华西医学,2009,24(4):885-887. 被引量:7
  • 10National Institute for health and clinical excellence. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. NICE short clinical guideline 87. London: NICE, 2009.

二级参考文献19

  • 1王琼.胰岛β细胞的休息与保护[J].护理研究(上旬版),2005,19(9):1706-1708. 被引量:1
  • 2刘军,查英,盛励,陈灶萍,陈钦达,廖晓寰,吴强,孟令平.腹型肥胖患者胰岛β细胞功能和胰岛素敏感性的变化[J].复旦学报(医学版),2006,33(3):393-396. 被引量:24
  • 3BERGMAN RN, FINEGOOD DT, KAHN SE. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes[J].Eur J Clin Invest, 2002,32(Suppl 3) : 35-45.
  • 4PORTE JR D. Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications[J]. Diabetes Metab Res Rev,2001, 17:181-188.
  • 5GAREIA GV, FREEMAN RV, SUPIANO MA,et al. Glucose metabolism in older adults: A study including subjects more than 80 years of age[J]. J Geriatr Soc,1997,45:813-817.
  • 6MENEILLY CS, DAWSON K, TESSIER D. Alterations in glucose metabolism in the elderly patient with diabetes[J]. Diabetes Care,1993,16:1241-1248.
  • 7SHIMIZU M, KAWAZU S, TOMONO S, et al. Age-related alteration of pancreatic β-cell function; Increased proinsulin and proinsulin-to-insulin molar ratio in elderly, but not in obese, subjects without glucose intolerance[J]. Diabetes Care, 1996,19 : 8-11.
  • 8MORLEY JE. An overview of diabetes mellitus in older persons[J]. Clin Geriatr Med 1999 15:211-224.
  • 9MORI Y, HOSHINO K, YOKOTA K,et al. Increased visceral fat and impaired glucose tolerance predict the increased risk of metabolic syndrome in Japanese middle-aged men[J]. Exp Clin Endocrinol Diabetes, 2005,113(6) :334.
  • 10Nishikawa T, Araki E. Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications[J]. Antioxid Redox Signal,2007 ;9(3 ) :343-53.

共引文献47

同被引文献298

  • 1Bo Ahrén.Insulin plus incretin:A glucose-lowering strategy for type 2-diabetes[J].World Journal of Diabetes,2014,5(1):40-51. 被引量:6
  • 2李美芝,李蓉.多囊卵巢综合征诊断的金标准:鹿特丹标准?[J].中国实用妇科与产科杂志,2007,23(9):657-659. 被引量:153
  • 3中华医学会糖尿病学分会.中国2型糖尿病防治指南/2010年版[M].北京:北京大学医学出版社,2011:5.
  • 4Liu W J,Xie S H,Liu Y N,et al. Dipeptidyl peptidase IV inhibitor at- tenuates kidney injury in streptozotocin - induced diabetic rats [ J ]. The Journal of pharmacology and experimental therapeutics, 2012,340 ( 2 ) : 248 - 255.
  • 5Yang W,Lu J,Weng J. Prevalence of diabetes among men and women in China[J].{H}New England Journal of Medicine,2010,(12):1090-1101.
  • 6Drucker DJ,Nauck MA. The incretin system:glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes[J].{H}LANCET,2006,(9548):1696-1705.
  • 7Mentlein R,Gallwitz B,Schmidt WE. Dipeptidyl-peptidase Ⅳ hydrolyses gastric inhibitory polypeptide,glucagon-like peptide-1 (7-36) amide,peptide histidine methionine and is responsible for their degradation in human serum[J].{H}European Journal of Biochemistry,1993,(03):829-835.
  • 8Oxman AD. Checklists for review articles[J].{H}BMJ:British Medical Journal,1994,(6955):648.
  • 9Senn S. The quality of systematic reviews.Review is biased[J].{H}BMJ:British Medical Journal,2000,(7256):297.
  • 10Berhan A,Berhan Y. Efficacy of alogliptin in type 2 diabetes treatment:a meta-analysis of randomized double-blind controlled studies[J].{H}BMC Endocrine Disorders,2013,(01):9.

引证文献36

二级引证文献310

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部